Zoryve Topical Foam Approved for Seborrheic Dermatitis

The FDA has approved Zoryve® (roflumilast) topical foam, 0.3% for the treatment of seborrheic dermatitis in patients 9 years of age and older.

Related Keywords

Oregon ,United States ,Arcutis Biotherapeutics ,Andrew Blauvelt ,Drug Administration ,Oregon Medical Research Center ,Zoryve Direct Program ,Investigator Global Assessment ,Worst Itch Numeric Rating Scale ,